Copyright
©The Author(s) 2024.
World J Gastrointest Surg. Apr 27, 2024; 16(4): 1087-1096
Published online Apr 27, 2024. doi: 10.4240/wjgs.v16.i4.1087
Published online Apr 27, 2024. doi: 10.4240/wjgs.v16.i4.1087
Table 1 Comparison of general information, n (%)/mean ± SD
Factor | Non-ALF | ALF | t/z/χ2 | P value |
n = 148 | n = 46 | |||
Gender | 0.382 | 0.537 | ||
Male | 88 (59.5) | 24 (52.2) | ||
Female | 60 (40.5) | 22 (47.8) | ||
Age | 49.0 ± 4.0 | 51.1 ± 5.9 | -2.719 | 0.007 |
BMI (kg/m2) | 23.454 ± 1.29 | 23.830 ± 1.424 | -1.620 | 0.110 |
Hypertension | 0.65 | 0.42 | ||
Yes | 52 (35.1) | 12 (26.1) | ||
None | 96 (64.9) | 34 (73.9) | ||
Diabetes | 0.394 | 0.53 | ||
Yes | 42 (28.4) | 10 (21.7) | ||
None | 106 (71.6) | 36 (78.3) | ||
History of hepatitis | 23.454 ± 1.29 | 23.830 ± 1.424 | -2.026 | 0.043 |
Yes | 103 (69.6) | 39 (84.8) | ||
None | 45 (30.4) | 7 (15.2) | ||
Liver cirrhosis | -2.026 | 0.043 | ||
Yes | 103 (69.6) | 39 (84.8) | ||
None | 45 (30.4) | 7 (15.2) | ||
Envelope integrity | -1.548 | 0.122 | ||
Complete | 127 (85.8) | 35 (76.1) | ||
Incomplete | 21 (14.2) | 11 (23.9) | ||
Tumor type | -0.331 | 0.74 | ||
Isolated | 119 (80.4) | 38 (82.6) | ||
Nodal fusion | 29 (19.6) | 8 (17.4) | ||
Number of tumors | -0.975 | 0.33 | ||
Single | 125 (84.5) | 36 (78.3) | ||
Multiple | 23 (15.5) | 10 (21.7) | ||
Surgical procedure | -2.269 | 0.023 | ||
Open | 85 (57.4) | 35 (76.1) | ||
Abdominal | 63 (42.6) | 11 (23.9) | ||
Portal vein cancer plug | -1.804 | 0.071 | ||
Negative | 136 (91.9) | 38 (8236) | ||
Positive | 12 (8.1) | 8 (17.4) | ||
BLV (mL) | 343.8 ± 97.9 | 418.2 ± 72.7 | -5.554 | 0.000 |
Table 2 Comparison of laboratory data, n (%)/mean ± SD
Factor | Non-ALF | ALF | t/z/χ2 | P value |
n = 148 | n = 46 | |||
AFP | -2.6 | 0.009 | ||
≤ 400 (ng/mL) | 113 (76.4) | 26 (56.5) | ||
> 400 (ng/mL) | 35 (23.6) | 20 (43.5) | ||
Hb (g/L) | 134.47 ± 21.418 | 129.74 ± 19.509 | 1.336 | 0.183 |
PLT (× 109/L) | 155.107 ± 31.693 | 135.661 ± 27.468 | 3.746 | 0 |
WBC (× 109/L) | 5.669 ± 0.956 | 5.613 ± 0.970 | 0.345 | 0.73 |
PT (s) | 12.2 ± 1.2 | 12.9 ± 1.2 | -3.337 | 0.001 |
TBil (μmol/L) | 16.778 ± 7.345 | 19.152 ± 7.472 | -1.907 | 0.058 |
DBIL (μmol/L) | 4.0 ± 2.8 | 5.0 ± 2.6 | -2.221 | 0.027 |
ALT (u/L) | 50.692 ± 15.477 | 48.687 ± 14.367 | 0.78 | 0.436 |
AST (u/L) | 43.562 ± 14.151 | 45.339 ± 13.180 | 0.756 | 0.451 |
Table 3 Multifactorial analysis influencing the occurrence of alanine aminotransferase after R0 for hepatocellular carcinoma
Factor | β | SE | OR value | 95%CI | Wald value | P value |
AFP | 1.401 | 0.539 | 4.058 | 1.411-11.670 | 6.755 | 0.009 |
BLV | 0.009 | 0.003 | 1.009 | 1.003-1.016 | 9.166 | 0.002 |
NLR | 1.464 | 0.277 | 4.318 | 2.511-7.426 | 27.969 | 0.000 |
ALBI | 2.157 | 0.665 | 8.646 | 2.350-31.816 | 10.531 | 0.001 |
Table 4 Value of alpha-fetoprotein, blood loss volume, neutrophil-to-lymphocyte ratio, and albumin-bilirubin score in predicting the development of acute liver failure after R0 surgery for hepatocellular carcinoma
Indicator | Cut-off value | AUC | 95%CI | Specificity | Sensitivity | P value |
AFP | 400 | 0.599 | 0.643-0.793 | - | - | 0.042 |
BLV | 302.850 | 0.718 | 0.643-0.793 | 1.000 | 0.432 | 0.000 |
NLR | 3.150 | 0.767 | 0.659-0.875 | 1.000 | 0.696 | 0.000 |
ALBI | -1.942 | 0.755 | 0.640-0.870 | 0.824 | 0.783 | 0.000 |
- Citation: Li XP, Bao ZT, Wang L, Zhang CY, Yang W. Construction of a predictive model for acute liver failure after hepatectomy based on neutrophil-to-lymphocyte ratio and albumin-bilirubin score. World J Gastrointest Surg 2024; 16(4): 1087-1096
- URL: https://www.wjgnet.com/1948-9366/full/v16/i4/1087.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v16.i4.1087